Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bgp products gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcio chloridum dihydricum, magnesio chloridum hexahydricum, il resto: ovalbuminum max. 0,1 µg, formaldehydum e cetrimidum e polysorbatum 80 e gentamicinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - haemagglutininum influenzae di tipo a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) mente.15 µg e neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) mente.15 µg e neuraminidasum inactivatum (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b mente.15 µg e neuraminidasum inactivatum (virus-stamm b/brisbane/60/2008), natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesio chloridum hexahydricum, calcio chloridum dihydricum, acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b ), haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lignaggio)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/brisbane/60/2008 (victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus souche b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, il resto: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg sintetiche, no, neomycinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/guangdong-maonan/swl1536/2019 (h1n1)-like: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus nib-121 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 3 jahren - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (ceppo del virus a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (ceppo del virus a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus ivr-186), haemagglutininum influenzae b (virus del ceppo b/colorado/06/2017-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016 (victoria lignaggio)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: reassortant virus wild type derived from b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - impfstoffe